Source-grounded facts extracted from ARTELO BIOSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ARTELO BIOSCIENCES, INC. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to an aggregate of $6,530,000 (effective 2026-05-26).
“On May 26, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) to create an at-the-market equity program under which it may sell up to an aggregate of $6,530,000 of shares of the Company’s common stock”
ARTELO BIOSCIENCES, INC. terminated Sales Agreement with R.F. Lafferty & Co., Inc. valued at up to $6,500,000 (effective 2026-05-18).
“On May 11, 2026, Artelo Biosciences, Inc. (the “Company”) provided notice to R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) of its election to terminate that certain At-The-Market Offering Agreement, dated July 18, 2025, by and between the Company and R.F. Lafferty (the “Sales Agreement”), which termination will be effective on May 18, 2026, in accordance with the terms of the Sales Agreement.”
ARTELO BIOSCIENCES, INC. issued warrants to purchase 255,073 shares of common stock of warrant to designees of the Placement Agent (H.C. Wainwright & Co., LLC) for issuance to designees of the Placement Agent.
“In addition, the Company issued to designees of the Placement Agent warrants to purchase 255,073 shares of Common Stock at an exercise price of $4.3125 per share (the “Placement Agent Warrants”), which have the same terms as the Common Warrants other than the exercise price.”
ARTELO BIOSCIENCES, INC. issued warrants to purchase 6,376,814 shares of common stock of warrant to certain accredited investors for Each Share or, at the election of the Purchaser in lieu of Shares, each Pre-Funded Warrant, was issued and sold along with two Common Warrants.
“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”
ARTELO BIOSCIENCES, INC. issued pre-funded warrants to purchase 3,107,407 shares of common stock of warrant to certain accredited investors for $3.449 per Pre-Funded Warrant and two Common Warrants.
“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”
ARTELO BIOSCIENCES, INC. issued 81,000 shares of common stock of common stock to certain accredited investors for $3.45 per share.
“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”
ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).
“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors”
ARTELO BIOSCIENCES, INC. issued convertible note to Labrys Fund II, L.P. for aggregate purchase price of $300,000.00.
“On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).”
ARTELO BIOSCIENCES, INC. entered into Securities Purchase Agreement with Labrys Fund II, L.P. valued at aggregate principal amount of $315,000.00 (effective 2026-03-20).
“On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).”
ARTELO BIOSCIENCES, INC. issued convertible note to Boot Capital LLC for aggregate principal amount of $113,000.00, which includes an original issue discount of $13,000.00, for an aggregate purchase price of $100,000.00.
“limited liability company (“Boot” and together with Vanquish , the “Buyers”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $113,000.00, which includes an original issue discount of $13,000.00, for an aggregate purchase price of $100,000.00 (the “Boot Note” and together with the Vanquish Note, the “Notes”). The”
ARTELO BIOSCIENCES, INC. issued convertible note to Vanquish Funding Group Inc. for aggregate principal amount of $237,300.00, which includes an original issue discount of $27,300.00, for an aggregate purchase price of $210,000.00.
“Agreement”), with Vanquish Funding Group Inc., a Virginia corporation (“Vanquish”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $237,300.00, which includes an original issue discount of $27,300.00, for an aggregate purchase price of $210,000.00 (the “Vanquish Note”). Additionally, on March 12, 2026, the Company”
ARTELO BIOSCIENCES, INC. entered into Boot Purchase Agreement with Boot Capital LLC valued at $100,000.00 (effective 2026-03-12).
“Additionally, on March 12, 2026, the Company entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Boot Purchase Agreement” and together with the Vanquish Purchase Agreement, the “Purchase Agreements”), with Boot Capital LLC, a Delaware limited liability company (“Boot” and together with Vanquish , the “Buyers”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $113,000.00, which includes an original issue discount of $13,000.00, for an aggregate purchase price of $100,000.00 (the “Boot Note” and together with the Vanquish Note, the “Notes”).”
ARTELO BIOSCIENCES, INC. entered into Vanquish Purchase Agreement with Vanquish Funding Group Inc. valued at $210,000.00 (effective 2026-03-12).
“On March 12, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Vanquish Purchase Agreement”), with Vanquish Funding Group Inc., a Virginia corporation (“Vanquish”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $237,300.00, which includes an original issue discount of $27,300.00, for an aggregate purchase price of $210,000.00 (the “Vanquish Note”).”
ARTELO BIOSCIENCES, INC. issued common stock.
“on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split ("Reverse Split") of the Company’s common stock ("Common Stock").”
ARTELO BIOSCIENCES, INC.: Effected a one-for-three reverse stock split of common stock and reduced authorized shares accordingly (effective 2026-03-10).
“On March 5, 2026, Artelo Biosciences, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-three (1-for-3) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).”
ARTELO BIOSCIENCES, INC. issued up to $25 million (the “Initial Commitment Amount”) in shares of common stock of common stock to Square Gate Capital Master Fund, LLC – Series 5 for 95% of the lowest daily VWAP of the Common Stock.
“applicable Put Date, or (iii) $500,000, subject to waiver by Square Gate in its sole discretion. The purchase price to be paid by Square Gate for the Regular Put Amount will be 95% of the lowest daily VWAP (as defined in the Purchase Agreement) of the Common Stock during the three trading days immediately following the applicable Put Date (the “Regular”
ARTELO BIOSCIENCES, INC. issued 292,398 shares of Common Stock of common stock to Square Gate Capital Master Fund, LLC – Series 5 for aggregate value, as of January 30, 2026, of $500,000.
“In consideration for Square Gate’s execution and delivery of the Purchase Agreement, the Company will issue 292,398 shares of Common Stock to Square Gate (the “Commitment Shares”), having an aggregate value, as of January 30, 2026, of $500,000, as shares and/or as pre-funded warrants.”
ARTELO BIOSCIENCES, INC. entered into Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 valued at up to $25 million (effective 2026-01-30).
“On January 30, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an Equity Purchase Agreement, dated as of January 30, 2026 (the “Purchase Agreement”), with Square Gate Capital Master Fund, LLC – Series 5, a series limited liability company organized in the state of Delaware (“Square Gate”), pursuant to which the Company has the right, but not the obligation, to direct Square Gate to purchase up to $25 million (the “Initial Commitment Amount”) in shares of common stock”
ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
“January 14, 2026, the Company received a letter from the Staff of Nasdaq (the “Nasdaq Notice”) indicating that it is not in compliance with Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires companies listed on Nasdaq to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year-end, and, as a result, does not currently satisfy the Annual Meeting Rule. The Staff indicated in the Nasdaq Notice that the Company’s non-compliance with the Annual Meeting Rule could be an additional basis for a delisting determination. The Company ac”
ARTELO BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“ndicated that unless the Company requests a hearing panel appeal of the delist determination by November 26, 2025, its securities would be delisted on December 1, 2025. The Company intends to appeal Nasdaq’s determination to a hearing panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any further delisting actions through the hearing or any extension the hearings panel provides. Following the appeal request, the Company’s common stock, par value $0.001 per share, will continue to trade on Nasdaq under the symbol “ARTL.” 2 SIGNATURES Pursuant to the requir”
ARTELO BIOSCIENCES, INC.: Eliminated stockholder right to fill Board vacancies and provided that directors are elected by plurality vote (effective 2025-11-10).
“On November 10, 2025, the board of directors (the “Board”) of Artelo Biosciences, Inc. (the “Company”) amended the Company’s amended and restated bylaws (the “Bylaws”), as provided in a Certificate of Amendment to Bylaws (the “Bylaws Amendment”), as follows: · The Bylaws have been updated to provide that the right of stockholders to fill vacancies in the Board has been eliminated; and · The Bylaws have been updated to provide that directors shall be elected at a meeting of the stockholders by a plurality of the votes cast at the election.”
ARTELO BIOSCIENCES, INC. issued 438,182 shares of common stock underlying warrants of warrant to certain investors for Part of the same consideration as the notes; warrants issued in the same transaction.
“On October 28, 2025, Artelo Biosciences, Inc. (the " Company ") entered into a Subscription Agreement (the " Subscription Agreement ") pursuant to which it issued and sold to certain investors (the " Investors "), and the Investors purchased (by converting all or a portion of the unconverted "Voluntary Conversion" portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the " Notes ") to the Investors in an aggregate principal amount of $690,154.69; and (ii) warrants (the " Warrants ") to purchase an aggregate of 438,182 shares of the Company's common stock, par value $0.001 per share (" Common Stock "), at an exercise price of $3.40 per share (collectively, the " Offering ").”
ARTELO BIOSCIENCES, INC. issued Aggregate principal amount of $690,154.69 of convertible notes of convertible note to certain investors for Conversion of all or a portion of the unconverted 'Voluntary Conversion' portion of unpaid principal balance and accrued interest due upon maturity of convertib.
“On October 28, 2025, Artelo Biosciences, Inc. (the " Company ") entered into a Subscription Agreement (the " Subscription Agreement ") pursuant to which it issued and sold to certain investors (the " Investors "), and the Investors purchased (by converting all or a portion of the unconverted "Voluntary Conversion" portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the " Notes ") to the Investors in an aggregate principal amount of $690,154.69; and (ii) warrants (the " Warrants ") to purchase an aggregate of 438,182 shares of the Company's common stock, par value $0.001 per share (" Common Stock "), at an exercise price of $3.40 per share (collectively, the " Offering ").”
ARTELO BIOSCIENCES, INC. incurred convertible notes of $690,154.69 at 12% per annum maturing six months after the closing of the Notes Offering.
“On October 28, 2025, Artelo Biosciences, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) pursuant to which it issued and sold to certain investors (the “ Investors ”), and the Investors purchased (by converting all or a portion of the unconverted “Voluntary Conversion” portion of unpaid principal balance and accrued interest due to such Investors upon the maturity of the convertible promissory notes issued to the Investors on May 1, 2025): (i) convertible notes (the “ Notes ”) to the Investors in an aggregate principal amount of $690,154.69;”
ARTELO BIOSCIENCES, INC.: Amended bylaws to change special meeting notice period, eliminate stockholder action by written consent, clarify status as issuing corporation under NRS 78.378-78.3793, and set record date limit of 60 days (effective 2025-09-09).
“On September 9, 2025, the board of directors (the “Board”) of Artelo Biosciences, Inc. (the “Company”) amended the Company’s amended and restated bylaws, as provided in a Certificate of Amendment to Bylaws (the “Bylaws Amendment”), as follows: · The required notice period for special meetings of the Board has been updated, as provided in the Bylaws Amendment; · The right of stockholders to take action without a meeting has been eliminated; · The Bylaws have been updated to provide that the Company shall in all respects be considered an “issuing corporation” for purposes of the provisions of NRS 78.378 to 78.3793 inclusive, irrespective of whether the Company, as of any date, (i) has 200 or more stockholders of record, at least 100 of whom have had addresses in Nevada appearing on the stock ledger of the Company at all times during the 90 days immediately preceding such date, and/or (ii) does business in Nevada directly or through an affiliated corporation; and · The Bylaws have been up”
ARTELO BIOSCIENCES, INC.: Effected a one-for-six reverse stock split of common stock and proportionally reduced authorized shares (effective 2025-06-13).
“On June 12, 2025, Artelo Biosciences, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a Certificate of Change (the “Certificate of Change”), pursuant to Nevada Revised Statutes 78.209, to effect a one-for-six (1-for-6) reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”).”
ARTELO BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 22, 2025, Artelo Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its Quarterly Report for the quarterly period ended March 31, 2025, the Company reported stockholders’ equity of $652,000, and, as a result, does not currently satisfy Nasdaq Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of t”
ARTELO BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 23, 2025, Artelo Biosciences, Inc. (the “ Company ”) received written notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, subject to Nasdaq’s discretion, the closing bid price of the Compa”
ARTELO BIOSCIENCES, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-30 meeting.
“The appointment of Malone Bailey LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain 1,049,839 41,188 29,212”
ARTELO BIOSCIENCES, INC. shareholders approved Election of Directors at the 2023-06-30 meeting.
“The Class I nominees were elected by the holders of our common stock for a one-year term, to serve until the 2024 annual meeting of stockholders, the Class II nominees were elected by the holders of our common stock for a two-year term, to serve until the 2025 annual meeting of stockholders, and the Class III nominees were elected by the holders of our common stock for a three-year term, to serve until the 2026 annual meeting of stockholders, and in each case, until their respective successor, if any, is duly elected and qualified:”
ARTELO BIOSCIENCES, INC.: Amended and restated bylaws to establish a classified board of directors with three classes and staggered three-year terms (effective 2023-04-21).
“On April 21, 2023, the board of directors (the “Board”) of Artelo Biosciences, Inc. (the “Company”) amended and restated the Company’s amended and restated bylaws to establish a classified board of directors, divided into three classes, each of whose members will serve for staggered three year terms.”
John W. Beck departed as Member of the Board of Directors and Chair of the Audit Committee at ARTELO BIOSCIENCES, INC..
“the untimely and unexpected death of Mr. John W. Beck on July 20, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.